Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SecondCANCERinKIDS

Financiado

What causes therapy related malignancies in childhood cancer survivors? Dissecti...

What causes therapy related malignancies in childhood cancer survivors? Dissecting the etiology of second cancers Therapy-related malignancies are a major cause of long-term mortality among childhood cancer survivors. However, it is unclear how exposure to chemo- and/or radiotherapy early in life induces carcinogenesis. My aim is to determine... ver más

31/03/2025

PrinsesMaximaCentr...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-03-19

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100% 100%

2 Participantes

PrinsesMaximaCentrumvoorKind...

2.00M€ | Lider

CENOCLAP, S.A.

308.22K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNS2023-144908 Biología molecular y celular 400K€ Cerrado

RTI2018-093314-B-I00 DESENCADENANTE INFECCIOSO EN LA PB-ALL INFANTIL - DESCIFRAND... 290K€ Cerrado

CONTEXT Aneuploidy and Its Impact on Blood Development: Context Matt... 2M€ Cerrado

PID2021-122185OB-I00 CONTEXTO INMUNOLOGICO Y EVOLUCION TUMORAL EN LA LEUCEMIA LIN... 454K€ Cerrado

SAF2012-35342 BUSQUEDA DE NUEVAS DIANAS TERAPEUTICAS EN LEUCEMIA MIELOIDE... 117K€ Cerrado

SAF2016-75442-R GENERACION DE NOVO DE LEUCEMIA T LINFOBLASTICA AGUDA (T-ALL)... 290K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2020-03-19
Fecha Fin: 2025-03-31

Líder del proyecto

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE B... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Therapy-related malignancies are a major cause of long-term mortality among childhood cancer survivors. However, it is unclear how exposure to chemo- and/or radiotherapy early in life induces carcinogenesis. My aim is to determine the mechanisms and rate-limiting steps underlying the genesis of second malignancies in childhood cancer survivors. For this, we will focus on studying the etiology of therapy-related myeloid malignancies (t-MNs). I have pioneered methods to characterize mutation accumulation in single stem cells and study clonal lineages in the human hematopoietic system. My lab is embedded in Europe’s largest childhood cancer center, providing the opportunity to apply our techniques to unique patient material. In Objective 1, we will dissect the life history of t-MN and study its cellular origin. Our key question is: Was the original t-MN clone already present before chemotherapy exposure, or generated as a consequence thereof? We will address this by tracking back clonal lineages in the hematopoietic tissue of patients using the mutations present in their second cancers. In Objective 2, we will study the mutational consequences of chemotherapy in normal hematopoietic cells of children before and after they received treatment. Our key question is: Is enhanced mutagenesis rate limiting for t-MN development? To address this, we will perform in-depth mutational analyses and in vitro validations. In Objective 3, we will determine phenotypic effects of chemotherapy on population dynamics of blood. Our key question is: how does chemotherapy affect selection dynamics and clonal composition of blood? To address this, we will integrate clonal histories and lineage contributions using somatically acquired mutations. Our unique methodology and anticipated novel insights will not contribute to improved survival of children with cancer, but also to increased fundamental knowledge on the origin of cancer.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores